Treatments in Phase 1 Trials


Name: CC-90006
Indication: Psoriasis

  • Celgene
  • PD-1 Agonist Antibody

Name: MSB11022
Indication: Psoriasis

  • EMD Serono
  • Biosimilar for Humira (adalimumab)
  • TNF-alpha inhibitor

Oral Treatments

Name: ABBV-157
Indication: Psoriasis

  • Abbvie
  • RoRγT Inhibitor

Name: CC-92252
Indication: Psoriasis

  • Celgene
  • Interleukin-2 receptor agonists; Regulatory T-lymphocyte stimulants

Name: EDP1066
Indication: Psoriasis

  • Evelo Biosciences
  • Monoclonal microbial

Name: EDP1815
Indication: Psoriasis

  • Evelo Biosciences, Inc.
  • Monoclonal microbial


Name: BOS-475
Indication: Psoriasis

  • Boston Pharmaceuticals
  • Selective BET (Bromodomain and Extra-Terminal) inhibitor

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logoTwill Care logo

Copyright © 1996-2022 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.